These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31252002)

  • 21. Urologist compliance with AUA best practice guidelines for benign prostatic hyperplasia in Medicare population.
    Strope SA; Elliott SP; Saigal CS; Smith A; Wilt TJ; Wei JT;
    Urology; 2011 Jul; 78(1):3-9. PubMed ID: 21601254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. American Urological Association Nonmuscle Invasive Bladder Cancer Risk Model Validation-Should Patient Age be Added to the Risk Model?
    Ravvaz K; Weissert JA; Downs TM
    J Urol; 2019 Oct; 202(4):682-688. PubMed ID: 31188732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guideline of guidelines: non-muscle-invasive bladder cancer.
    Woldu SL; Bagrodia A; Lotan Y
    BJU Int; 2017 Mar; 119(3):371-380. PubMed ID: 28058776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non-muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection.
    Del Giudice F; Barchetti G; De Berardinis E; Pecoraro M; Salvo V; Simone G; Sciarra A; Leonardo C; Gallucci M; Catalano C; Catto JWF; Panebianco V
    Eur Urol; 2020 Jan; 77(1):101-109. PubMed ID: 31699526
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic performance and predictive capacity of early urine cytology after transurethral resection of nonmuscle invasive bladder cancer: A prospective study.
    Elsawy AA; Harraz AM; Ghobrial FK; Abdullatef M; Ali-El-Dein B
    Urol Oncol; 2020 Dec; 38(12):935.e1-935.e8. PubMed ID: 32654947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer.
    Williams SB; Shan Y; Jazzar U; Mehta HB; Baillargeon JG; Huo J; Senagore AJ; Orihuela E; Tyler DS; Swanson TA; Kamat AM
    JAMA Surg; 2018 Oct; 153(10):881-889. PubMed ID: 29955780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer.
    Balakrishnan AS; Washington SL; Meng MV; Porten SP
    Clin Genitourin Cancer; 2019 Jun; 17(3):e461-e471. PubMed ID: 30799130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are we following the guidelines on non-muscle invasive bladder cancer?
    Reis LO; Moro JC; Ribeiro LF; Voris BR; Sadi MV
    Int Braz J Urol; 2016; 42(1):22-8. PubMed ID: 27136464
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use and Validation of the AUA/SUO Risk Grouping for Nonmuscle Invasive Bladder Cancer in a Contemporary Cohort.
    Ritch CR; Velasquez MC; Kwon D; Becerra MF; Soodana-Prakash N; Atluri VS; Almengo K; Alameddine M; Kineish O; Kava BR; Punnen S; Parekh DJ; Gonzalgo ML
    J Urol; 2020 Mar; 203(3):505-511. PubMed ID: 31609178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment and surveillance for non-muscle-invasive bladder cancer: a clinical practice guideline (2021 edition).
    Jin YH; Zeng XT; Liu TZ; Bai ZM; Dou ZL; Ding DG; Fan ZL; Han P; Huang YR; Huang X; Li M; Li XD; Li YN; Li XH; Liang CZ; Liu JM; Ma HS; Qi J; Shi JQ; Wang J; Wang DL; Wang ZP; Wang YY; Wang YB; Wei Q; Xia HB; Xing JC; Yan SY; Zhang XP; Zheng GY; Xing NZ; He DL; Wang XH;
    Mil Med Res; 2022 Aug; 9(1):44. PubMed ID: 35978389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).
    Babjuk M; Burger M; Capoun O; Cohen D; Compérat EM; Dominguez Escrig JL; Gontero P; Liedberg F; Masson-Lecomte A; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Seisen T; Soukup V; Sylvester RJ
    Eur Urol; 2022 Jan; 81(1):75-94. PubMed ID: 34511303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Continuous saline bladder irrigation after blue light transurethral resection of bladder tumor increases recurrence-free survival in low- to intermediate-risk non-muscle invasive bladder cancer.
    Gondran-Tellier B; Abdallah R; Sichez PC; Akiki A; Toledano H; Gaillet S; Delaporte V; Karsenty G; Bastide C; Daniel L; Garcia S; Rossi D; Lechevallier E; Boissier R; Baboudjian M
    Prog Urol; 2021 May; 31(6):316-323. PubMed ID: 33663939
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Familiarity and self-reported compliance with American Urological Association best practice recommendations for use of thromboembolic prophylaxis among American Urological Association members.
    Sterious S; Simhan J; Uzzo RG; Gershman B; Li T; Devarajan K; Canter D; Walton J; Fogg R; Ginzburg S; Corcoran A; Smaldone MC; Kutikov A
    J Urol; 2013 Sep; 190(3):992-8. PubMed ID: 23538239
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Management of Newly-Diagnosed Non-muscle Invasive Bladder Cancer in Veterans Integrated Services Network 02 of the Veterans Health Administration.
    Caputo JM; Moran G; Muller B; Keller AT; Li G; Anderson CB
    Mil Med; 2020 Feb; 185(1-2):276-281. PubMed ID: 31294791
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.
    Steinberg RL; Thomas LJ; Brooks N; Mott SL; Vitale A; Crump T; Rao MY; Daniels MJ; Wang J; Nagaraju S; DeWolf WC; Lamm DL; Kates M; Hyndman ME; Kamat AM; Bivalacqua TJ; Nepple KG; O'Donnell MA
    J Urol; 2020 May; 203(5):902-909. PubMed ID: 31821066
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
    Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
    Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
    Wang H; Ding W; Jiang G; Gou Y; Sun C; Chen Z; Xu K; Xia G
    Medicine (Baltimore); 2018 Sep; 97(36):e12006. PubMed ID: 30200080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline.
    Chang SS; Boorjian SA; Chou R; Clark PE; Daneshmand S; Konety BR; Pruthi R; Quale DZ; Ritch CR; Seigne JD; Skinner EC; Smith ND; McKiernan JM
    J Urol; 2016 Oct; 196(4):1021-9. PubMed ID: 27317986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Urine Cytology Rarely Escalates Clinical Management in the Surveillance of Non-muscle-Invasive Bladder Cancer.
    Feiertag N; Barry E; Abramson M; Park JY; Kovac E; Aboumohamed A; Watts K; Sankin A
    Clin Genitourin Cancer; 2023 Apr; 21(2):258-264. PubMed ID: 36621462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ranking Important Factors for Using Postoperative Chemotherapy in Nonmuscle Invasive Bladder Cancer: Conjoint Analysis Results From the Michigan Urological Surgery Improvement Collaborative (MUSIC).
    Cary C; Tong Y; Linsell S; Ghani K; Miller DC; Weiner M; Koch MO; Perkins SM; Zimet G
    J Urol; 2022 Feb; 207(2):293-301. PubMed ID: 34551594
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.